Trial Profile
A Phase I Study to Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety, Efficacy and Pharmacokinetics Profiles of TSB-9-W1 in Pre-treated Patients With Metastatic Colorectal Cancer (mCRC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs TSB 9-W1 (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions
- Sponsors Taiwan Sunpan Biotechnology Development
- 05 Oct 2020 Status changed from suspended to completed.
- 09 Jan 2018 Planned number of patients changed from 30 to 12.
- 09 Jan 2018 Planned End Date changed from 1 Nov 2017 to 31 Dec 2018.